In Silico In Action: A Case Study In Relapsing Remitting Multiple Sclerosis

In clinical research, computer modeling and simulation of humans, both healthy and with diseases, can be a powerful study tool. Through otherwise impossible mechanistic and predictive investigations, it can support preclinical and clinical research. In recent years, regulatory agencies have begun to accept evidence obtained through modeling and simulation, and in silico clinical trials have emerged as an important approach for the virtual testing of pharmacological therapies and medical devices. 

During an in silico recreation of a clinical trial for relapsing-remitting multiple sclerosis, researchers found that 90% of patients in the treatment group were relapse-free, compared to 40% in the placebo group. Based on the study’s findings, learn how in silico recreation can be a valuable tool for predicting the efficacy of new treatments.